Fintel reports that on July 30, 2025, William Blair downgraded their outlook for CyberArk Software (NasdaqGS:CYBR) from Outperform to Market Perform. Analyst Price Forecast Suggests 4.72% Upside As of ...

Fintel reports that on July 29, 2025, William Blair downgraded their outlook for Neogen (NasdaqGS:NEOG) from Outperform to ...

Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

William Blair analyst Matt Larew maintained a Hold rating on Amedisys today. The company’s shares closed yesterday at $97.52. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

FTI Consulting’s second quarter results drew a positive market response as the company delivered solid performance despite flat year-over-year sales and notable headwinds. Management cited ongoing ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the best long term low volatility stocks to buy now. On July 16, William ...

Detailed price information for Healthcare Svcs Gp (HCSG-Q) from The Globe and Mail including charting and trades.

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...